Trade Name (Agent): Imbruvica (ibrutinib)
Sponsor: Pharmacyclics LLC
Date of BT Designation Disclosure: 4/08/2013
Approval Date: 7/28/2014
Indication: Patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and CLL with 17p deletion
Category: Cancer